Wells Fargo’s Cognition Therapeutics CGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.24K Buy
6,500
+3,500
+117% +$3.52K ﹤0.01% 6213
2026
Q2
$3.45K Sell
3,000
-50
-2% -$59 ﹤0.01% 6290
2026
Q1
$2.32K Buy
3,050
+50
+2% +$58 ﹤0.01% 6234
2025
Q4
$4.05K Sell
3,000
-1,000
-25% -$1.62K ﹤0.01% 6136
2025
Q3
$5.4K Buy
4,000
+3,000
+300% +$4.09K ﹤0.01% 6063
2025
Q2
$310 Hold
1,000
– – ﹤0.01% 6417
2025
Q1
$421 Hold
1,000
– – ﹤0.01% 6278
2024
Q4
$701 Hold
1,000
– – ﹤0.01% 6291
2024
Q3
$469 Hold
1,000
– – ﹤0.01% 6176
2024
Q2
$1.66K Buy
1,000
+854
+585% +$1.7K ﹤0.01% 6044
2024
Q1
$266 Buy
146
+10
+7% +$21 ﹤0.01% 6431
2023
Q4
$252 Buy
136
+8
+6% +$11 ﹤0.01% 6548
2023
Q3
$184 Sell
128
-9
-7% -$14 ﹤0.01% 6607
2023
Q2
$251 Buy
137
+13
+10% +$28 ﹤0.01% 6636
2023
Q1
$246 Sell
124
-38,386
-100% -$73.1K ﹤0.01% 6720
2022
Q4
$80.9K Sell
38,510
-38,417
-50% -$77.6K ﹤0.01% 4638
2022
Q3
$146K Buy
76,927
+60
+0.1% +$125 ﹤0.01% 4411
2022
Q2
$162K Buy
76,867
+76,843
+320,179% +$199K ﹤0.01% 4393
2022
Q1
$0 Hold
24
– – ﹤0.01% 7116
2021
Q4
$0 Buy
+24
New +$234 ﹤0.01% 7261

Other funds holding CGTX

Wells Fargo's CGTX Position: Q3 2026 in Review

Wells Fargo increased its Cognition Therapeutics (CGTX) stake by 117% in Q3 2026, buying an estimated $3.52K and bringing the position to 6,500 shares worth $6.24K. The position accounts for ﹤0.01% of the portfolio, ranked #6213.

Wells Fargo first reported a position in CGTX in Q4 2021 and has held it in 20 quarters since. The position peaked at $162K in Q2 2022. 78 funds tracked by Wall St. Rank hold CGTX as of Q3 2026.

  • Wells Fargo held 6,500 shares of Cognition Therapeutics worth $6.24K as of Q3 2026.
  • Wells Fargo bought 3,500 Cognition Therapeutics shares in Q3 2026, an estimated $3.52K.
  • Cognition Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q3 2026, its #6213 holding.
  • Wells Fargo first reported a position in Cognition Therapeutics in Q4 2021 and has held it in 20 quarters since.
  • Wells Fargo's Cognition Therapeutics position peaked at $162K in Q2 2022.
  • 78 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q3 2026.

Based on Wells Fargo's 13F filing for Q3 2026, filed 16 Nov 2026.